BACKGROUND: Thoracic epidural analgesia has been shown to be an effective method of pain control. The utility of epidural analgesia as part of an enhanced recovery after surgery protocol is debatable.
nhanced recovery after surgery (ERAS) protocols are a mainstay in colorectal surgery. A critical component of ERAS protocols is multimodal analgesia. 1,2 Despite its importance, the specifics of multimodal analgesia are not standardized and can vary widely between institutions. 3, 4 The primary goal of multimodal analgesia is to avoid the delivery of systemic opioids. Although effective for pain control, systemic opioids slow colonic motility and increase postoperative ileus. 5 A common regional anesthesia technique used for postoperative pain control in abdominal surgery is thoracic epidural analgesia (TEA). [6] [7] [8] Thoracic epidural analgesia may be used within ERAS pathways and delivers local anesthetic with or without opioids. 6, 7, 9 In a Cochrane review of 128 trials with 8754 patients, the use of TEA with abdominal surgery was associated with a quicker return of bowel function, improved pain control, and decreased length of hospital stay. 8 However, these benefits are not as clear in colorectal surgery. In initial studies comparing TEA with systemic opioids in colorectal surgery, epidural analgesia was found to provide better pain control, decrease the incidence of ileus, and induce a quicker return of bowel function. [10] [11] [12] [13] [14] Yet, recent studies have been unable to confirm these benefits and, in fact, have shown a greater risk of hypotension and urinary retention with TEA. [15] [16] [17] [18] A major difference between these 2 bodies of work is the presence of ERAS multimodal pain protocols in more recent studies.
Given the lack of consistent data, we sought to examine the effect of TEA on immediate postoperative pain control and overall inpatient recovery within our ERAS protocol. After noting recent publications doubting the utility of TEA in an ERAS protocol, we questioned whether our utilization of TEA was beneficial. Our aim was to examine our experience to discern if TEA had resulted in an improvement in length of stay or systemic opioid consumption when applied as a standard adjunct to all patients receiving colorectal surgery.
MATERIALS AND METHODS
This is a retrospective review of all patients undergoing elective transabdominal colon or rectal resection by specialty-trained colon and rectal surgeons at a tertiary care center from 2013 to 2017. This study was approved by our Institutional Review Board. Utilizing our own institutional participation in the American College of Surgeons National Surgical Quality Improvement Program, all patients in this cohort were identified at our hospital. Per institutional protocol, all patients were considered for TEA. In addition, standard ERAS protocol during this time period utilized a multimodal pain regimen including patient-controlled analgesia (PCA) with intravenous opioids and scheduled nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentin, and oral acetaminophen. Other ERAS elements included preoperative immunonutrition, mechanical bowel preparation with oral antibiotics, intravenous antibiotic prophylaxis, thromboprophylaxis, and administration of alvimopan. Intraoperatively and postoperatively, a fluid-restrictive/ goal-directed strategy was utilized. Postoperative early removal of the Foley catheter (postoperative day (POD) 3 for low pelvic dissections and POD 1 for all others), POD 0 mobilization, and early initiation of an oral diet were used.
Patient variables abstracted from the American College of Surgeons National Surgical Quality Improvement Program database included demographics (age, sex, BMI), comorbid conditions, and overall length of stay (LOS, time from date of elective surgery to date of discharge). To measure opioid consumption, we queried our institutional pharmacy database used to track administration of all medications administered as an inpatient. Pharmacy data have been available since 2015. Standard TEA concentration was 0.1% bupivacaine without opioid. Oral morphine milligram equivalents were calculated by converting all opioid medications consumed utilizing validated resources. 19, 20 Analysis was performed comparing those who received TEA with bupivacaine and those who did not. All patients were considered for TEA; patients were ruled out if deemed inappropriate for TEA. Data regarding exactly why individual patients were ruled out for TEA were not collected at the time of surgery and therefore unavailable in this retrospective review. Anecdotal questioning of the surgeons operating during this time period showed that reasons for not utilizing TEA included patient preference, anatomically prohibitive/failed placement of epidural catheter, and preoperative anticoagulation/antiplatelet status. A pain management team made rounds on the patients postoperatively and weaned the patient off of TEA as their pain was controlled with other medications.
Board-certified anesthesiologists performed all epidural catheter insertions. Epidural catheter location was, in part, determined by the location of the incisions. The desired sensory nerve block from TEA should cover the length of the incision (or extraction incision in the case of minimally invasive surgery), but there are other considerations. For example, a more cephalad block may be associated with greater episodes of hypotension, and a more caudal location increases the rate of urinary retention. [21] [22] [23] [24] [25] For left-sided and rectal resections with lower abdominal incisions, T10 was the most common level used. For right-sided resections with more cephalad incisions, placement at T8 or T9 was often utilized.
Primary outcome was the difference in LOS between those receiving TEA and those not receiving TEA; secondary outcome was oral morphine milligram equivalents consumed during the first 48 hours. Univariate regression was performed to determine the differences in LOS and opioid consumption for patients receiving TEA and those who did not. Because we were interested in immediate postoperative pain control and all epidural catheters were in place for at least 2 days, we only considered opioid consumption within the first 2 postoperative days. Multivariable linear regressions were then performed utilizing the demographics outlined in Table 1 to determine if the use of TEA affected LOS or morphine equivalent consumption within the first 48 hours. Stratified analyses of both primary and secondary outcomes by operative approach were also performed. Both LOS and opioid consumption were considered to be continuous variables and modeled by using linear regression techniques.
RESULTS
There were 1006 patients (520 women, 486 men) who underwent colorectal resection during the study period. Demographic characteristics between those receiving TEA or not receiving TEA were similar at baseline (see Table 1 ), although there were some differences. Patients receiving TEA included a greater percentage of patients with ASA class 1 or 2, and a greater percentage of patients received a minimally invasive approach than an open approach. Median age was 59 years (interquartile range (IQR) 52-69) and median BMI was 27.6 (IQR, 25-32). Diabetes mellitus was present in 13.2% of patients, hypertension was present in 45.8%, and 23.3% of patients were smokers. Metastatic disease was present in 14.2% of patients, 14.1% of patients had baseline dyspnea, and 17.6% of patients were on steroids preoperatively. American Society of Anesthesiologists class 1 or 2 applied to 52.6% of patients, and thus 3 or 4 in 47.4% of patients. Right-sided resections were performed in 39% of patients, and left-sided or rectal resections were performed in 61% of patients. Thoracic epidural analgesia was given in 815 patients (81%) of the overall cohort.
Univariate analysis demonstrated no statistically significant difference in LOS between those who received TEA and those who did not (median, 4 vs 5 days; mean, 5.7 vs 6.1 days; p = 0.16; IQR, 3-7 days for both groups). Multivariable linear regression further substantiated this (p = 0.40; see Table 2 ). Multivariable linear regression identified these factors increasing LOS: open approach (p < 0.001), presence of metastatic disease (p = 0.02), preoperative dyspnea (p = 0.04), and ASA 3 or 4 (p = 0.046). Minimally invasive approach was associated with decreased LOS by an average of 2.2 days compared with open surgery (p < 0.001). Stratified analysis of LOS by operative approach was then performed. Again, the addition of TEA resulted in no statistically significant difference in LOS regardless of open (median = 6 vs 6 days; p = 0.82; IQR 5-7 for both groups, n = 362) or minimally invasive (median = 4 vs 4 days; p = 0.94; IQR 3-5 for both groups, n = 644) approach in both univariate and multivariable regression analyses (see Tables 3 and 4) .
Inpatient opioid consumption data were only available after 2015 (n = 497 patients, 399 TEA, 98 no TEA). Both orally and parenterally administered opioids were included in the analysis. Univariate analysis demonstrated no statistically significant difference in oral morphine milligram equivalents consumed in the first 48 hours (MME48) between patients who received TEA and those who did not (median, 135; IQR, 118-150 vs 110; IQR, 92-130 oral morphine milligram equivalents; p = 0.35), which was substantiated by multivariable linear regression (see Table 5 
DISCUSSION
Our results show that, in the context of multimodal analgesia and an ERAS pathway, the use of TEA had no impact on length of stay or in-hospital opioid consumption following colorectal surgery. As seen in Table 1 , the 2 groups were similar with regard to demographics. Multivariable linear regression did not show a difference in LOS with the addition of TEA to a multimodal analgesia regimen. As seen in Table 2 , the use of a minimally invasive approach significantly decreases the LOS in our data set, with a 95% CI of -1.6 to -2.7 days. This is in line with other studies that have shown a decrease in LOS with minimally invasive colorectal surgery, 26, 27 and it further validates our data set. Although recent studies have contested the utility of TEA in elective laparoscopic colectomy, TEA has previously been noted to have its greatest efficacy in open abdominal surgery. 8 Thus, a subgroup analysis was performed to evaluate whether there was any effect on LOS within either the minimally invasive or open groups. As seen in Tables 3 and 4 , the addition of TEA did not change LOS in either of these groups. Other variables in our multivariable linear regression models found to contribute to increasing LOS (metastases, dyspnea, ASA 3 or 4, and heart failure) are comorbidities that would not unexpectedly increase LOS (see Tables 2-4 ).
In addition, pharmacy data were examined to see if using TEA had any effect on opioid consumption. We found no benefit of TEA to a multimodal analgesia regimen. It was not surprising that the use of a minimally invasive approach significantly decreases the MME48 in our data set. This is in line with other studies that show lower pain scores and need for pain medication with minimally invasive colorectal surgery, 26, 27 and further validates our data set. Again, because TEA has been shown to have its greatest efficacy in open abdominal surgery, 8 a subgroup analysis was performed to determine if there was any difference in opioid consumption rates when TEA was added to a minimally invasive or open approach. This showed that there was no alteration in MME48 when TEA was used with either a minimally invasive or an open approach. Other variables found to contribute to increasing MME48 in our multivariable linear regression included smoking and ASA 3 or 4. It is unclear why this occurred. Last, increased age correlated with a decrease in MME48. This is in line with other work that has shown the same correlation. 28 Studies examining whether the benefits of TEA apply specifically to the field of colorectal surgery have yielded mixed results. A 2001 randomized trial by Carli et al 11 compared 21 patients undergoing elective colorectal surgery who received postoperative epidural analgesia with 21 patients who were administered morphine PCA. They found superior pain control and quicker time to first flatus and bowel movement in the TEA group. However, discharge to home was not faster (7.3 days in the PCA group vs 8.5 days in the TEA group). 11 In 2009, Zingg et al 14 randomly assigned 75 patients undergoing elective colorectal surgery to TEA and non-TEA groups. The TEA group had less analgesic consumption, better pain relief, and faster recovery of GI function. Of note, the only scheduled opioid-sparing analgesic used in their protocol was acetaminophen. A 2007 meta-analysis by Marret et al 10 examining all studies comparing TEA and parenteral opioid administration in colorectal surgery echoed these findings. Analyzing 16 trials between 1987 and 2005, this group discovered that TEA significantly reduced pain scores and duration of ileus. On the other hand, they found an increase in pruritis, episodes of hypotension, and urinary retention. There was no effect of TEA on LOS.
The benefits of TEA have more recently been challenged in colorectal surgery. As ERAS protocols have expanded, so has the utilization of multimodal analgesia regimens with opioid-sparing agents, including gabapentinoids, NSAIDs, acetaminophen, lidocaine, ketamine, and 15 randomly assigned 87 patients undergoing elective laparoscopic colorectal surgery to TEA vs intravenous opioid analgesia within an ERAS pathway utilizing nonopioid multimodal analgesia. The TEA group had more episodes of hypotension, longer urinary catheter duration, and greater use of narcotics. There was no difference in LOS.
Limitations of this study include incomplete data regarding preoperative narcotic use and decision making leading to TEA omission. Because all patients were considered for TEA placement per protocol, epidurals were likely not omitted at random among this population. In addition, the epidural rate used for TEA could not be assessed, only if the patient received TEA or not. Also, outside the scheduled opioid-sparing medications such as gabapentin, NSAIDs, and acetaminophen used in the institutional protocol, use of additional adjuncts such as intravenous lidocaine infusion and transversus abdominis plane blocks was not standardized, and these adjuncts were used intermittently. Because of the study's retrospective nature, data points not previously recorded such as pain scores and return of GI function could not be measured. In addition, type of minimally invasive surgery was not standardized. The minimally invasive group included hand-assist laparoscopic surgery, total laparoscopic surgery, and robotic surgery. This work agrees with recent studies that have questioned the benefit of TEA in colorectal surgery. Among our large study of clinical outcomes from a tertiary specialty practice, we failed to show a clinical benefit of TEA in elective colorectal surgery. Historically, some studies did show a clinical benefit. It is likely, however, that more recent studies have failed to show this benefit because widespread adoption of ERAS pathways with multimodal opioid-sparing analgesia has emerged. Thoracic epidural analgesia is not without risk, because epidurals in colorectal surgery have been associated with increased fluid boluses for hypotension and increased urinary retention. 10, 15 Additional risks include bleeding (1:10,000) and infection (1:10,000), which occur infrequently. 29 Thoracic epidural analgesia also adds an additional cost, because utilization requires additional resources because a pain management team typically places the catheter and manages the epidural regimen postoperatively. It should be emphasized that this study adds to the literature with a novel finding of no clinical benefit of TEA in open elective colon and rectal surgery. We believe that this is due to adherence to an ERAS protocol that overcomes any benefit of TEA shown by previous studies in open surgery.
This study did not find a reduction of LOS or MME48 with the addition of TEA to an ERAS protocol that used a multimodal analgesia regimen. In light of the costs and potential side effects of this adjunct without demonstrable benefit in this large series, we cannot recommend routine use of TEA within ERAS protocols. Further prospective studies are warranted to confirm our findings. 
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